Leap Therapeutics, Inc.

2.83 USD
0.00 (0.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Leap Therapeutics, Inc. stock is up 82.58% since 30 days ago. The next earnings date is Mar 22, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 57.14% of the previous 6 December’s closed higher than November. 100% of analysts rate it a buy.

About Leap Therapeutics, Inc.

Leap Therapeutics, Inc. acquires and develops therapies for the treatment of cancer. DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers.

  • Mizuho
    Mon Nov 20, 10:38
  • Raymond James
    Tue Nov 14, 03:41